Revista espanola de medicina nuclear e imagen molecular最新文献

{"title":"Single metastasis of cutaneous malignant melanoma in the gallbladder detected with 18F-FDG PET/CT","authors":"A. Bota-Bota, M. Pombo-López, I. Martínez-Rodríguez, F. Gómez-de la Fuente, J. Jiménez-Bonilla, R. Quirce","doi":"10.1016/j.remnie.2025.500120","DOIUrl":"10.1016/j.remnie.2025.500120","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 3","pages":"Article 500120"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal and pulmonary malakoplakia with mediastinal involvement simulating a synchronous neoplasm in PET/CT study with [18F]FDG","authors":"J.R. Garcia, A. Compte, S. Romero, L. Mont, L. Pinilla, E. Riera","doi":"10.1016/j.remnie.2025.500124","DOIUrl":"10.1016/j.remnie.2025.500124","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 3","pages":"Article 500124"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of [18F]FDG PET/CT in the management of primary bone lymphoma","authors":"M.M. Losada , I.G. Megías , R.M. Losada , L.G.R. Robles , X.B. Chollet , R.R. Lasanta","doi":"10.1016/j.remnie.2025.500126","DOIUrl":"10.1016/j.remnie.2025.500126","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 3","pages":"Article 500126"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natriuretic factors and inflammation biomarkers as predictors of survival in [¹⁷⁷Lu]Lu-DOTA-TATE therapy of neuroendocrine tumors.","authors":"A Piñeiro Donis, L Menéndez-Muros, J L Villa-Palacios, E Triviño-Ibáñez, M A Muros-Fuentes","doi":"10.1016/j.remnie.2025.500138","DOIUrl":"https://doi.org/10.1016/j.remnie.2025.500138","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the prognostic value of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and other biomarkers of inflammation in patients with neuroendocrine tumors (NETs) treated with [¹⁷⁷Lu]Lu-DOTA-TATE (Lutathera®). The prognostic value of histological characteristics of the tumor was also analyzed.</p><p><strong>Patients and methods: </strong>Prospective study of a cohort of patients with advanced and metastatic NETs treated with [¹⁷⁷Lu]Lu-DOTA-TATE. Before the administration of doses, NT-proBNP, hemoglobin, hematocrit, C-reactive protein, leukocytes, lymphocytes, neutrophils, neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) have been determined. Overall survival (OS) and progression free survival (PFS) were calculated, using the Kaplan-Meier method, and curves were compared with a log-rank test. To determine the predictor variables of OS, a Cox regression model was fitted.</p><p><strong>Results: </strong>48 NET patients treated with [177Lu]Lu-DOTA-TATE. Median OS was 96 months and PFS was 29 months. Factors associated with lower OS were: NTproBNP values>300 pg/mL (HR: 10,5; p = 0,005) in the subgroup of patients with grades 2-3, in addition to inflammatory indices NLR > 2 (HR: 3,87; p = 0,049) and PLR > 300 (HR: 11,88; p = 0,01) and higher tumor grade (HR: 6,45; p = 0,011). PLR > 300 (HR: 5,506; p = 0,003) was also associated with lower PFS. In contrast, higher levels of lymphocytes (HR: 0,21; p = 0,002), hemoglobin (HR: 0,65; p = 0,041) and hematocrit (HR: 0,862; p = 0,031) were associated with higher OS, without significant changes in PFS.</p><p><strong>Conclusion: </strong>In patients with NETs treated with [¹⁷⁷Lu]Lu-DOTA-TATE, the determination of natriuretic factors (NT-ProBNP) and other inflammatory biomarkers may be useful as predictors of survival and prognostic factors.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500138"},"PeriodicalIF":0.0,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143813226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary intestinal amyloidosis visualized on a scintigraphy with [m99Tc]Tc-HMDP","authors":"S. Bondia-Bescós ,&nbsp;I.E. Sánchez-Rodríguez ,&nbsp;A. Palomar-Muñoz ,&nbsp;P. Notta ,&nbsp;M. Cortés-Romera ,&nbsp;L.M. Gràcia-Sánchez","doi":"10.1016/j.remnie.2024.500070","DOIUrl":"10.1016/j.remnie.2024.500070","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 2","pages":"Article 500070"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microparticle disease in hip prostheses: A case report","authors":"J.L. Díaz Moreno,&nbsp;I.E. Sánchez-Rodríguez,&nbsp;B. Hervás-Sanz,&nbsp;P. Notta-González,&nbsp;C. Martínez-Ramos,&nbsp;L. Gràcia-Sánchez","doi":"10.1016/j.remnie.2024.500078","DOIUrl":"10.1016/j.remnie.2024.500078","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 2","pages":"Article 500078"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical value of a negative [18F]F-PSMA PET/CT study in patients diagnosed with prostate cancer treated with prostatectomy with PSA rising below 1 ng/mL after radical prostatectomy, on the outcome of salvage radiotherapy","authors":"M. Cózar Santiago ,&nbsp;J. García Garzón ,&nbsp;A. Esteban Hurtado ,&nbsp;J. Pastor Peiro ,&nbsp;J. Ferrer Rebolleda","doi":"10.1016/j.remnie.2025.500071","DOIUrl":"10.1016/j.remnie.2025.500071","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the clinical value of [¹⁸F]F-PSMA negative PET/CT, in patients diagnosed with prostate cancer treated with prostatectomy with elevated PSA less than 1 ng/mL, on the outcome of salvage radiotherapy.</div></div><div><h3>Method</h3><div>We prospectively included 98 patients diagnosed with prostate cancer treated with prostatectomy with biochemical recurrence [mean PSA 0.51 ng/mL (range 0.17–1.0 ng/mL)] who were referred for an [¹⁸F]F-PSMA -PET/CT study.</div><div>The [¹⁸F]F-PSMA -PET/CT scan was negative in 53/98 patients (54.09%). Differences were analysed between those patients who were or were not candidates for pelvic salvage radiotherapy (PSRT) decided upon multidisciplinary committee and patient consent, with a minimum follow-up time for 1 year. Response to treatment was defined as a 50% reduction in PSA levels. Recurrence was ascertained upon clinical, analytical and imaging follow-up outcomes.</div></div><div><h3>Results</h3><div>54.7% (29/53) of the patients with a negative [¹⁸F]F-PSMA -PET/CT underwent PSRT.</div><div>Of these, 93.1% (27/29) patients demonstrated response to treatment (PSMA false negatives).</div><div>The remaining two patients showed fluctuating PSA levels without detecting disease on the [¹⁸F]F-PSMA -PET/CT follow-up study.</div><div>45.3% (24/53) of patients with negative [¹⁸F]F-PSMA -PET/CT did not undergo PSRT.</div><div>Of these, progressive PSA elevation was observed in 62.5% (15/24) (PSMA false negatives), localising recurrence on the [¹⁸F]F-PSMA -PET/CT follow-up study in 4 patients.</div><div>The remaining 9 patients (37.5%) showed fluctuating PSA levels without detecting disease on the [¹⁸F]F-PSMA -PET/CT follow-up study.</div><div>Our series confirmed 42 (42.85%) [¹⁸F]F-PSMA -PET/CT false negatives cases.</div></div><div><h3>Conclusion</h3><div>Patients diagnosed with prostate cancer with post-prostatectomy biochemical recurrence and a negative [¹⁸F]F-PSMA -PET/CT study are likely to benefit from pelvic salvage radiotherapy, with response seen in 93.1% of our cases.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 2","pages":"Article 500071"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Utility of PET/CT with [18F] F-fluorocholine in assessing the response to antiandrogenic therapy in patients with prostate cancer.\"","authors":"K. Quintero ,&nbsp;E. Vila ,&nbsp;L. Ferrer-Mileo ,&nbsp;D. Vas ,&nbsp;Maria J. Ribal ,&nbsp;M. Garcia-Herreros ,&nbsp;N. Navarro ,&nbsp;M. Tormo-Ratera ,&nbsp;C. Aversa ,&nbsp;A. Vilaseca ,&nbsp;A. Farré-Melero ,&nbsp;D. Fuster ,&nbsp;P. Paredes ,&nbsp;grupo de Medicina Nuclear Clínic Barcelona (MNCB)","doi":"10.1016/j.remnie.2025.500083","DOIUrl":"10.1016/j.remnie.2025.500083","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the correlation between response assessment measured by PET/CT with [¹⁸F] F-fluorocholine (Choline PET/CT) and serum levels of PSA in patients with prostate cancer under antiandrogenic treatment.</div></div><div><h3>Methodology</h3><div>A retrospective study included patients with CRPC (castration-resistant prostate cancer) and HSPC (hormone sensitive prostate cancer) treated with enzalutamide, abiraterone, or apalutamide between June 2018 and July 2021, who underwent baseline and a follow-up Choline PET/CT. The difference in maximum SUVmax (ΔSUV) between both studies and the PSA value before and at follow-up were recorded. The response to treatment was compared by PSA vs. PET, assessing their association, agreement, and correlation.</div></div><div><h3>Results</h3><div>Thirty patients were included (median age 74 years, range 68–78), 12 with CSPC and 18 with CRPC; 22 had nodal disease, and 15 had active bone disease. The average time between pre-treatment and follow-up PET/CT was 11 months (range 3.5–23).</div><div>Patients with extra-nodal metastatic disease at the beginning of treatment showed a higher correlation between PSA and ΔSUV (OR 4.375). In patients with bone disease at the start of treatment, 80% were classified as non-responders on PET response assessment, while only 40% were non-responders by PSA.</div><div>The correlation between PET and PSA was mild <em>(Kendall’s tau_b</em> 0.26), and the classification into Responders/Non-responders had only slight agreement (<em>Cohen’s kappa</em> 0.30).</div></div><div><h3>Conclusion</h3><div>Choline PET/CT shows low concordance with the PSA values obtained during the follow-up of response to anti-androgen therapy, especially in patients with bone involvement.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 2","pages":"Article 500083"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of pulmonary nodules using [18F]-FDG PET/CT in deep inspiration breath-hold","authors":"M.S. Casallas Cepeda,&nbsp;S. Salcedo Córtes,&nbsp;I. Gómez Fernández,&nbsp;J. Orcajo Rincón,&nbsp;L. Reguera Berenguer,&nbsp;E.J. Ardila Manjarrez,&nbsp;J.J. Ardila Mantilla,&nbsp;V. Castillo Morales,&nbsp;J. Gúzman Cruz,&nbsp;D. Zamudio Rodríguez,&nbsp;A. Marí Hualde,&nbsp;J.E. Montalvá Pastor,&nbsp;S. Álvarez Lara,&nbsp;J.C. Alonso Farto","doi":"10.1016/j.remnie.2024.500074","DOIUrl":"10.1016/j.remnie.2024.500074","url":null,"abstract":"<div><div>The characterization of pulmonary nodules (PN) is a primary indication for [¹⁸F]-FDG PET/CT. However, respiratory movements hinder this characterization, especially for PN located in the lower lobes. Various methods have been developed to improve image resolution.</div></div><div><h3>Objective</h3><div>Our objective was to compare the diagnostic efficacy of [¹⁸F]-FDG PET/CT in deep inspiration breath-hold (DIBH) versus free-breathing corrected by software, in the evaluation of PN.</div></div><div><h3>Methods</h3><div>We prospectively analyzed 51 patients to assess PN using [¹⁸F]-FDG PET/CT in DIBH and free-breathing corrected by software. A total of 84 nodules with an average size of 10 mm were analyzed, with pathological anatomy or medical treatment decide by a multidisciplinary tumor board used as reference.</div></div><div><h3>Results</h3><div>A total of 84 PN were evaluated, comparing those in DIBH versus free-breathing, finding statistically significant differences in SUVmax values P(&lt; 0.05) (mean SUVmax 3.7 in free-breathing vs. 5.33 in DIBH). When analyzed by location in lobes, we did not find statistically significant differences, though there was a trend towards higher SUVmax values in the lower lobes. [¹⁸F]-FDG PET/CT in DIBH showed high sensitivity (95%) and negative predictive value (NPV) (92%), indicating it may be a promising tool for PN characterization.</div></div><div><h3>Conclusions</h3><div>The acquisition of [¹⁸F]-FDG PET/CT in DIBH significantly improves the sensitivity and diagnostic efficacy in the assessment of PN. Although no statistically significant differences were found based on location, there is a potential benefit for the lower lobes. These findings could support its use in clinical practice.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 2","pages":"Article 500074"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-FDG and 11C-PIB PET/TC findings in status epilepticus in the setting of a patient with mild cognitive impairment","authors":"M. Pombo-López,&nbsp;A. Bota-Bota,&nbsp;I. Martínez-Rodríguez,&nbsp;F. Gómez-de la Fuente,&nbsp;J. Jiménez-Bonilla,&nbsp;R. Quirce","doi":"10.1016/j.remnie.2024.500079","DOIUrl":"10.1016/j.remnie.2024.500079","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 2","pages":"Article 500079"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}